Ocular Therapeutix escapes SEC probe

The SEC recently closed its probe into Ocular Therapeutix (NSDQ:OCUL) and found no wrongdoing in the investigation.

Ocular Therapeutix received a subpoena from the SEC on Dec. 15, 2017, for documents and information pertaining to its Dextenza 0.4mg and related communication with the FDA, investors and other parties. The company received a second subpoena on Aug. 21, 2018, for documents and information about its participation in two investor conferences in June 2017.

Get the full story on our sister site, Drug Delivery Business.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston

At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.

Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.

REGISTER NOW